UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN

1. URGN shareholders can join a class action for misleading statements. 2. Allegations include flawed clinical study design of UGN-102. 3. Risk of NDA rejection for UGN-102 due to study issues. 4. Shareholders urged to register before July 28, 2025. 5. Gross Law Firm seeks justice for investors affected by potential fraud.

Legal

80

5m saved

Insight

Article

FAQ

Why Very Bearish?

The allegations suggest substantial risk to UGN-102's approval and credibility. Historical cases, like that of Akorn, demonstrate significant share price drops following FDA rejections.

How important is it?

The allegations directly impact URGN's pipeline credibility and stakeholder confidence, affecting future stock performance.

Why Long Term?

The outcome of this class action could affect URGN's market perception and investor trust well beyond 2025. Similar cases typically take years to resolve and can alter long-term investment strategies.

Related Companies

AKRX VRTX ULTR

NOTICE TO SHAREHOLDERS OF UROGEN PHARMA LTD.

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of UroGen Pharma Ltd. (NASDAQ: URGN).

Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

UroGen Pharma Loss Submission Form

CLASS PERIOD:

July 27, 2023 to May 15, 2025

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:

(1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company's lead pipeline product, UGN-102, because it lacked a concurrent control arm;
(2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102;
(3) UroGen failed to heed the FDA's warnings about the study design used to support a drug application for UGN-102;
(4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and
(5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

DEADLINE:

July 28, 2025. Shareholders should not delay in registering for this class action. Register your information here: UroGen Pharma Loss Submission Form

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of URGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 28, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903

SOURCE The Gross Law Firm